{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:11:46Z","timestamp":1787929906275,"version":"build-2784847793"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>To comprehensively assess the safety of Lifitegrast, a drug for dry eye disease, we conducted a comprehensive analysis of adverse event (AE) reports from the FDA Adverse Event Reporting System (FAERS). This retrospective study examined all AE reports submitted between Q3 2016 and Q2 2024, employing disproportionality analysis to identify safety signals associated with Lifitegrast. Out of a total of 13,326,934 AE reports indexed in the FAERS database, 12,393 listed Lifitegrast as the primary suspect drug. A total of 230 ocular AE signals were identified, with 104 of these AEs being detected by different analysis algorithms. Among these signals, 71 AEs were documented in the product insert of Lifitegrast, including but not limited to eye irritation, eye pain and eye swelling. AEs not mentioned in the drug labeling were identified, such as glaucoma and cataracts.AEs associated with Lifitegrast are more commonly observed in male patients and those aged over 65 years.The insights derived from this FAERS database analysis are significant for optimizing the use of Lifitegrast while minimizing potential side effects, thereby enhancing the safety of its clinical application.<\/jats:p>","DOI":"10.1371\/journal.pone.0321307","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T17:45:59Z","timestamp":1745516759000},"page":"e0321307","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-9856","authenticated-orcid":true,"given":"Chu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7824-6874","authenticated-orcid":true,"given":"Puen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"3","key":"pone.0321307.ref001","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"JP Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"pone.0321307.ref002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"issue":"1","key":"pone.0321307.ref003","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1186\/s12889-024-19616-1","article-title":"Prevalence of dry eye in people over 50 years old in Beichen district, Tianjin city: a cross-sectional population-based survey","volume":"24","author":"L Chang","year":"2024","journal-title":"BMC Public Health"},{"key":"pone.0321307.ref004","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"JD Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"pone.0321307.ref005","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1167\/iovs.11-9094","article-title":"Assessment of vision-related quality of life in dry eye patients","volume":"53","author":"M Li","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"pone.0321307.ref006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"B Miljanovi\u0107","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0321307.ref007","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, And Asia: a systematic literature review","volume":"14","author":"M McDonald","year":"2016","journal-title":"Ocul Surf"},{"issue":"2","key":"pone.0321307.ref008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"VL Perez","year":"2016","journal-title":"Ocul Surf"},{"issue":"14","key":"pone.0321307.ref009","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/14656566.2017.1372748","article-title":"Lifitegrast for the treatment of dry eye disease in adults","volume":"18","author":"ED Donnenfeld","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0321307.ref010","first-page":"2515841419870366","article-title":"Lifitegrast: a novel drug for patients with dry eye disease","volume":"11","author":"SL Haber","year":"2019","journal-title":"Ther Adv Ophthalmol"},{"issue":"2","key":"pone.0321307.ref011","first-page":"819-829.e2","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"RJ Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"pone.0321307.ref012","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA Adverse Event Reporting System (FAERS) Database","volume":"45","author":"M Fusaroli","year":"2022","journal-title":"Drug Saf"},{"key":"pone.0321307.ref013","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"C Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"pone.0321307.ref014","doi-asserted-by":"crossref","first-page":"e13331","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"L Meng","year":"2019","journal-title":"Int J Clin Pract"},{"key":"pone.0321307.ref015","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0321307.ref016","doi-asserted-by":"crossref","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Z Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0321307.ref017","doi-asserted-by":"crossref","first-page":"1044744","DOI":"10.3389\/fphar.2022.1044744","article-title":"Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database","volume":"13","author":"S Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"pone.0321307.ref018","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","article-title":"A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases","volume":"139","author":"C Khouri","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"pone.0321307.ref019","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"A Bate","year":"2007","journal-title":"Drug Saf"},{"key":"pone.0321307.ref020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of stevens-johnson syndrome and toxic epidermal necrolysis using the japanese adverse drug event report database","volume":"2","author":"J Abe","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"pone.0321307.ref021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"M Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"pone.0321307.ref022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"S Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"pone.0321307.ref023","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"O Sauzet","year":"2013","journal-title":"Drug Saf"},{"issue":"1","key":"pone.0321307.ref024","doi-asserted-by":"crossref","first-page":"32043","DOI":"10.1038\/s41598-024-83795-5","article-title":"Evaluating the impact of smoking on the risk of dry eye disease: a two-sample Mendelian randomization study","volume":"14","author":"K Yang","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0321307.ref025","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.survophthal.2023.07.001","article-title":"Secondhand smoke exposure and ocular health: A systematic review","volume":"68","author":"Y Zhang","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"pone.0321307.ref026","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtos.2023.11.003","article-title":"Recent advances in age-related meibomian gland dysfunction (ARMGD)","volume":"30","author":"I Moreno","year":"2023","journal-title":"Ocul Surf"},{"key":"pone.0321307.ref027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.matbio.2023.11.002","article-title":"Age related changes in hyaluronan expression leads to Meibomian gland dysfunction","volume":"124","author":"S Verma","year":"2023","journal-title":"Matrix Biol"},{"issue":"6","key":"pone.0321307.ref028","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/opo.12888","article-title":"The global prevalence of dry eye disease: a Bayesian view","volume":"41","author":"EB Papas","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"pone.0321307.ref029","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"ED Donnenfeld","year":"2016","journal-title":"Cornea"},{"issue":"12","key":"pone.0321307.ref030","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized Phase III OPUS-2 study","volume":"122","author":"J Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"pone.0321307.ref031","doi-asserted-by":"crossref","first-page":"781683","DOI":"10.1155\/2014\/781683","article-title":"Aging: a predisposition to dry eyes","volume":"2014","author":"A Sharma","year":"2014","journal-title":"J Ophthalmol"},{"issue":"2","key":"pone.0321307.ref032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/IIO.0000000000000170","article-title":"Effects of aging in dry eye","volume":"57","author":"CS de Paiva","year":"2017","journal-title":"Int Ophthalmol Clin"},{"issue":"9459","key":"pone.0321307.ref033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(05)70803-5","article-title":"Age-related cataract","volume":"365","author":"PA Asbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"pone.0321307.ref034","first-page":"154","article-title":"The epidemiology of glaucoma - an age-related disease","volume":"241","author":"C Wolfram","year":"2024","journal-title":"Klin Monbl Augenheilkd"},{"issue":"2","key":"pone.0321307.ref035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults-screening, diagnosis, and management: a review","volume":"325","author":"JD Stein","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"pone.0321307.ref036","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms driving gender differences in asthma","volume":"17","author":"H Fuseini","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"pone.0321307.ref037","doi-asserted-by":"crossref","first-page":"116385","DOI":"10.1016\/j.socscimed.2023.116385","article-title":"A Gender Hypothesis of sex disparities in adverse drug events","volume":"339","author":"KMN Lee","year":"2023","journal-title":"Soc Sci Med"},{"issue":"1","key":"pone.0321307.ref038","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s41256-024-00386-7","article-title":"Prevalence of potential drug\u2012drug interactions and associated factors among elderly patients in Ethiopia: a systematic review and meta-analysis","volume":"9","author":"TT Alemayehu","year":"2024","journal-title":"Glob Health Res Policy"},{"issue":"9","key":"pone.0321307.ref039","doi-asserted-by":"crossref","first-page":"e018283","DOI":"10.1136\/bmjopen-2017-018283","article-title":"Prevalence and associated factors of skin diseases in aged nursing home residents: a multicentre prevalence study","volume":"7","author":"E Hahnel","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"pone.0321307.ref040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s41999-020-00313-2","article-title":"Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient\u2019s experience","volume":"11","author":"M Maffoni","year":"2020","journal-title":"Eur Geriatr Med"},{"key":"pone.0321307.ref041","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"F Leroy","year":"2014","journal-title":"BMC Med Res Methodol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T17:46:11Z","timestamp":1745516771000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321307"}},"subtitle":[],"editor":[{"given":"Jingjing","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0321307","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}